Researchers at Stanford University have demonstrated rapid and accurate identification of extracellular vesicles (EVs) from different cell lines using an AI-assisted optical platform.
Stanford researchers have developed a modular system of Synthetic cytokine receptors (SCRs), which are customizable receptors that mimic cytokine signals to precisely control immune cell behavior without the need for external cytokines.
Researchers at Stanford have developed a clinically applicable method of bone marrow conditioning for stem cell transplantation or treatment of hematologic malignancies.
High-grade gliomas, including glioblastoma and diffuse midline glioma are the most common malignant brain tumor types and leading causes of brain-tumor-related death in adults and children, respectively.
Necrotizing enterocolitis is a life-threatening illness almost exclusively affecting the gastrointestinal tract of neonates. It's caused by bacterial invasion of the intestinal wall, which leads to inflammation and cellular destruction of the wall of the intestine.
Stanford researchers have developed a novel CRISPR-based method, Oligo-LiveFISH, for generating large-scale pools of synthetic RNA oligos that enable multiplexed targeting, imaging, and manipulation of genomic regions in living cells.
Pluripotent stem cells (PSCs) arise during early embryogenesis and can give rise to entire animals. Yet, comprehension of pluripotency regulation remains incomplete, highly species-specific, and primarily limited to mouse and human.
Researchers at Stanford University have developed a software that applies correction algorithms on sequence data from cell-free DNA (cfDNA) in blood samples to estimate total T and B cell counts.
Stanford scientists have discovered that Guanidinylated Serinol Charge-altering Releasable Transporters (GSer-CARTs) can be tuned for selective mRNA delivery to the lung and spleen in a predictable fashion.
Stanford scientists have discovered a DNA methylation signature on circulating tumor DNA (ctDNA) that can distinguish between the aggressive Leiomyosarcoma (LMS) from its benign counterpart leiomyoma (LM) in the uterus.
Researchers at Stanford have developed a novel T cell engineering platform that leverages constitutively active interleukin-9 receptor (IL-9R) signaling to improve the efficacy and scalability of immunotherapies for solid tumors.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Stanford researchers have developed the Large-scale Electrophysiology Amplification Platform (LEAP), a wireless, label-free optical system for monitoring the electrical activity of neurons and heart cells.